Results from a phase 1 study of nusinersen (ISIS-SMNRx) in children with spinal muscular atrophy
暂无分享,去创建一个
Jacqueline Montes | S. Iannaccone | K. Swoboda | C. Bennett | J. Montes | D. Norris | C. Chiriboga | K. Bishop | B. Darras | D. D. De Vivo | C Frank Bennett | Basil T Darras | Susan T Iannaccone | Daniel A Norris | Kathryn J Swoboda | Claudia A Chiriboga | Darryl C De Vivo | Kathie M Bishop | C. F. Bennett | Basil T. Darras | Kathryn J. Swoboda | Susan T. Iannaccone | Daniel A. Norris | C. Frank Bennett
[1] B. Steele. For More Information , 2000, Journal of the National Cancer Institute.
[2] W. Chung,et al. Observational study of spinal muscular atrophy type 2 and 3: functional outcomes over 1 year. , 2011, Archives of neurology.
[3] J. Varni,et al. The PedsQL: measurement model for the pediatric quality of life inventory. , 1999, Medical care.
[4] Elisa de Stanchina,et al. Determinants of exon 7 splicing in the spinal muscular atrophy genes, SMN1 and SMN2. , 2006, American journal of human genetics.
[5] W. Chung,et al. Prospective cohort study of spinal muscular atrophy types 2 and 3 , 2012, Neurology.
[6] Y. Hua,et al. Pharmacology of a Central Nervous System Delivered 2′-O-Methoxyethyl–Modified Survival of Motor Neuron Splicing Oligonucleotide in Mice and Nonhuman Primates , 2014, The Journal of Pharmacology and Experimental Therapeutics.
[7] M. Schroth,et al. SMA CARNI-VAL Trial Part I: Double-Blind, Randomized, Placebo-Controlled Trial of L-Carnitine and Valproic Acid in Spinal Muscular Atrophy , 2010, PloS one.
[8] J. Varni,et al. The PedsQL™ in pediatric patients with Spinal Muscular Atrophy: Feasibility, reliability, and validity of the Pediatric Quality of Life Inventory™ Generic Core Scales and Neuromuscular Module , 2009, Neuromuscular Disorders.
[9] K. Schlingensiepen,et al. The antisense oligonucleotide trabedersen (AP 12009) for the targeted inhibition of TGF-β2. , 2011, Current pharmaceutical biotechnology.
[10] A. D'Amico,et al. Randomized, double-blind, placebo-controlled trial of phenylbutyrate in spinal muscular atrophy , 2007, Neurology.
[11] A. Krainer,et al. Disruption of an SF2/ASF-dependent exonic splicing enhancer in SMN2 causes spinal muscular atrophy in the absence of SMN1 , 2002, Nature Genetics.
[12] Y. Hua,et al. Antisense masking of an hnRNP A1/A2 intronic splicing silencer corrects SMN2 splicing in transgenic mice. , 2008, American journal of human genetics.
[13] Adrian R. Krainer,et al. Peripheral SMN restoration is essential for long-term rescue of a severe SMA mouse model , 2011, Nature.
[14] S. Bratton,et al. Postdural Puncture Headache in Pediatric Oncology Patients , 1998, Clinical pediatrics.
[15] C. Sumner,et al. Spinal Muscular Atrophy Therapeutics: Where do we Stand? , 2015, Neurotherapeutics.
[16] J. Melki,et al. Spinal muscular atrophy. , 1997, Current opinion in neurology.
[17] A. Levin,et al. Pharmacokinetics of phosphorothioate antisense oligodeoxynucleotides. , 2001, Current opinion in investigational drugs.
[18] M. Main,et al. The Hammersmith functional motor scale for children with spinal muscular atrophy: a scale to test ability and monitor progress in children with limited ambulation. , 2001, European journal of paediatric neurology : EJPN : official journal of the European Paediatric Neurology Society.
[19] B. Russman. Spinal Muscular Atrophy: Clinical Classification and Disease Heterogeneity , 2007, Journal of child neurology.
[20] A. Levin,et al. Development of an ultrasensitive noncompetitive hybridization-ligation enzyme-linked immunosorbent assay for the determination of phosphorothioate oligodeoxynucleotide in plasma. , 2002, Analytical biochemistry.
[21] Ching H. Wang,et al. Consensus Statement for Standard of Care in Spinal Muscular Atrophy , 2007, Journal of child neurology.
[22] J. Weissenbach,et al. Identification and characterization of a spinal muscular atrophy-determining gene , 1995, Cell.
[23] R. Finkel,et al. An expanded version of the Hammersmith Functional Motor Scale for SMA II and III patients , 2007, Neuromuscular Disorders.
[24] A. Pestronk,et al. An antisense oligonucleotide against SOD1 delivered intrathecally for patients with SOD1 familial amyotrophic lateral sclerosis: a phase 1, randomised, first-in-man study , 2013, The Lancet Neurology.
[25] W. Chung,et al. Validation of the Expanded Hammersmith Functional Motor Scale in Spinal Muscular Atrophy Type II and III , 2011, Journal of child neurology.
[26] H. Berkenstadt,et al. Prospective Evaluation of Clinical and Laboratory Effects of Intrathecal Chemotherapy on Children With Acute Leukemia , 2005, Journal of pediatric hematology/oncology.
[27] Y. Hua,et al. Antisense Oligonucleotides Delivered to the Mouse CNS Ameliorate Symptoms of Severe Spinal Muscular Atrophy , 2011, Science Translational Medicine.
[28] R. Gur,et al. Age-related volumetric changes of brain gray and white matter in healthy infants and children. , 2001, Cerebral cortex.
[29] B. Darras. Spinal muscular atrophies. , 2015, Pediatric clinics of North America.
[30] Y. Hua,et al. Antisense correction of SMN2 splicing in the CNS rescues necrosis in a type III SMA mouse model. , 2010, Genes & development.
[31] J. Erickson,et al. Prevention and Management of Post–Lumbar Puncture Headache in Pediatric Oncology Patients , 2007, Journal of pediatric oncology nursing : official journal of the Association of Pediatric Oncology Nurses.
[32] E. Bertini,et al. Pilot trial of phenylbutyrate in spinal muscular atrophy , 2004, Neuromuscular Disorders.